We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LULU:NASDAQlululemon athletica inc. Analysis

Data as of 2026-09-06 - not real-time

$100.61

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind lululemon athletica inc. is neutral at $100.61, with no clear ordering between short and long averages. It has lost 12.0% over the past 30 days. With RSI at 31.8 the momentum picture is approaching oversold, alongside a bearish MACD signal. Watch $97.99 as support and $128.76 as the nearer resistance level.
Valuation screens as undervalued, on a P/E of 8.3 with no clean sector comparison available. Consensus targets land 26.6% above where the shares trade now. Revenue is contracting at 4.3% on a 12.8% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 67.4%, a beta of 1.24 and a maximum drawdown of 53.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.

Top Market Events

Joe Tenebruso, The Motley Fool Fri, September 4, 2026 at 9:55 PM UTC 0 Image source: Getty Images.Investing.com -- Lululemon Athletica Inc. NASDAQ:LULU reported second-quarter results that topped earnings expectations...Shares of athletic apparel retailer Lululemon NASDAQ:LULU fell 17.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 152.77
  • MACD momentum is negative
  • 30-day price change of -12.0%

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 152.77
  • Analyst targets imply +26.6% versus the current price
  • 30-day volatility of 67.4%

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Analyst targets imply +26.6% versus the current price
  • Revenue contracting at -4.3%
  • P/E ratio of 8.3

Key Metrics & Analysis

Financial Health

Revenue Growth-4.30%
Profit Margin12.78%
P/E Ratio8.3
ROE30.90%
ROA14.40%
Debt/Equity44.69
P/B Ratio2.4
Op. Cash Flow$2.0B
Free Cash Flow$1.1B

Technical Analysis

TrendNeutral
RSI31.8
Support$97.99
Resistance$128.76
MA 20$118.92
MA 50$118.40
MA 200$152.77
MACDBearish
VolumeIncreasing
Fear & Greed Index95.48

Valuation

Fair Value$124.55
Target Price$127.35
Upside/Downside26.57%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.24
Volatility67.35%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.